All In Biotech

Drug Trial Radar · NCT05565417

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Last checked: Nov 19, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

67

Actual

Start

Nov 28, 2022

Primary completion

Jan 2026

Study completion Jan 2026

Sponsor

Lead sponsor
Immunitas TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find the recommended dose of IMT-009 that can be safely given to participants * Learn more about the side effects of IMT-009 * Learn more about pharmacokinetics of IMT-009 * Learn more about the effectiveness of IMT-009 * Learn more about different pharmacokinetic biomarkers and how they might change in the presence of IMT-009

Conditions

  • Non Small Cell Lung Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Triple Negative Breast Cancer
  • Cutaneous Squamous Cell Carcinoma
  • Hormone Receptor Positive Breast Carcinoma
  • Small Bowel Cancer
  • Esophageal Cancer
  • Colorectal Cancer
  • Diffuse Large B Cell Lymphoma
  • Hodgkin Lymphoma
  • Burkitt Lymphoma
  • Follicular Lymphoma

Interventions

  • IMT-009Drug

    Participants will receive an IV infusion of IMT-009 on Day 1 during each 21-day cycle.

  • FruquintinibCombination product

    Fruquintinib will be administered according to the FDA-approved United States Prescribing Information (USPI).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation - number of participants with dose limiting toxicities (DLTs) from IMT-009 monotherapyTime frame: 21 days (Cycle 1 Day 1- Cycle 1 Day 21)
  2. Dose Escalation- Number of participants with adverse events following administration of IMT-009Time frame: From informed consent (Cycle 0 Day -28) to 90 days after the last dose of IMT-009. Each cycle is 21 days
  3. Phase 1b Cohort(s) number of participants with dose limiting toxicities (DLTs) from IMT-009 in combination with fruiquintinibTime frame: 28 days (Cycle 1 Day 1- Cycle 1 Day 28)
  4. Phase 1b Cohort(s) - Number of participants with adverse events following administration of IMT-009 in combination with fruiquintinibTime frame: From informed consent (Cycle 0 Day -28) through 90 days after last dose of IMT-009. Each cycle is 28 days
  5. Phase 2a Cohort(s) Overall Response Rate (ORR) based on RECIST 1.1 or Lugano criteria (lymphomas only) to assess anti-tumor activity of IMT-009 in each cohortTime frame: Every 6 weeks from Cycle 1 Day 1, until disease progression or death or start of a new anti-cancer therapy, up to 2 years. Each cycle is 21 days.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Site 9618

    Tucson, Arizona

  • Site 5000

    Denver, Colorado

  • Site 4100

    Orlando, Florida

  • Site 4060

    Sarasota, Florida

  • Site 4500

    Oklahoma City, Oklahoma

  • Site 9280

    Portland, Oregon

  • Site 3000

    Nashville, Tennessee

  • Site 9384

    Austin, Texas

  • Site 9112

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.